Green Cross Corp

KO:006280 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$1.16 Billion
₩1.69 Trillion KRW
Market Cap Rank
#9763 Global
#224 in Korea
Share Price
₩148300.00
Change (1 day)
-0.80%
52-Week Range
₩112800.00 - ₩180300.00
All Time High
₩493171.17
Categories
Companies in Korea Drug Manufacturers - Specialty & Generic
About

GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-… Read more

Green Cross Corp (006280) - Net Assets

Latest net assets as of September 2025: ₩1.49 Trillion KRW

Based on the latest financial reports, Green Cross Corp (006280) has net assets worth ₩1.49 Trillion KRW as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩3.19 Trillion) and total liabilities (₩1.70 Trillion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets ₩1.49 Trillion
% of Total Assets 46.67%
Annual Growth Rate 19.44%
5-Year Change 16.68%
10-Year Change 48.44%
Growth Volatility 60.12

Green Cross Corp - Net Assets Trend (2003–2024)

This chart illustrates how Green Cross Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Green Cross Corp (2003–2024)

The table below shows the annual net assets of Green Cross Corp from 2003 to 2024.

Year Net Assets Change
2024-12-31 ₩1.48 Trillion -3.82%
2023-12-31 ₩1.54 Trillion -1.71%
2022-12-31 ₩1.57 Trillion +4.46%
2021-12-31 ₩1.50 Trillion +18.16%
2020-12-31 ₩1.27 Trillion +7.20%
2019-12-31 ₩1.18 Trillion +5.14%
2018-12-31 ₩1.13 Trillion +1.58%
2017-12-31 ₩1.11 Trillion +4.69%
2016-12-31 ₩1.06 Trillion +6.14%
2015-12-31 ₩997.70 Billion +8.37%
2014-12-31 ₩920.63 Billion +9.68%
2013-12-31 ₩839.41 Billion +22.50%
2012-12-31 ₩685.23 Billion +8.72%
2011-12-31 ₩630.28 Billion +16.24%
2010-12-31 ₩542.23 Billion +191.56%
2006-12-31 ₩185.98 Billion +27.65%
2005-12-31 ₩145.70 Billion +33.73%
2004-12-31 ₩108.95 Billion +206.90%
2003-12-31 ₩35.50 Billion --

Equity Component Analysis

This analysis shows how different components contribute to Green Cross Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 81533563981000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings ₩815.34 Billion 65.09%
Other Components ₩437.31 Billion 34.91%
Total Equity ₩1.25 Trillion 100.00%

Green Cross Corp Competitors by Market Cap

The table below lists competitors of Green Cross Corp ranked by their market capitalization.

Company Market Cap
Chennai Petroleum Corporation Limited
NSE:CHENNPETRO
 		$552.36 Million
Shenzhen Bingchuan Network Co Ltd
SHE:300533
 		$552.40 Million
Sionna Therapeutics, Inc. Common Stock
NASDAQ:SION
 		$552.47 Million
Browave
TWO:3163
 		$552.58 Million
Heiwa Corporation
F:HWC
 		$551.90 Million
Media and Games Invest PLC
XETRA:M8G
 		$551.80 Million
Ningbo Menovo Pharm Co Ltd
SHG:603538
 		$551.56 Million
Metalla Royalty & Streaming Ltd
NYSE MKT:MTA
 		$551.52 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Green Cross Corp's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 1,300,236,293,690 to 1,252,644,924,130, a change of -47,591,369,560 (-3.7%).
  • Net loss of 26,280,215,150 reduced equity.
  • Dividend payments of 19,532,262,500 reduced retained earnings.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income ₩-26.28 Billion -2.1%
Dividends Paid ₩19.53 Billion -1.56%
Other Changes ₩-1.78 Billion -0.14%
Total Change ₩- -3.66%

Book Value vs Market Value Analysis

This analysis compares Green Cross Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.35x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 1.63x to 1.35x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 ₩91141.41 ₩148300.00 x
2018-12-31 ₩92840.80 ₩148300.00 x
2019-12-31 ₩91887.77 ₩148300.00 x
2020-12-31 ₩98002.82 ₩148300.00 x
2021-12-31 ₩111692.86 ₩148300.00 x
2022-12-31 ₩116367.45 ₩148300.00 x
2023-12-31 ₩113924.12 ₩148300.00 x
2024-12-31 ₩109754.26 ₩148300.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Green Cross Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -2.10%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -1.56%
  • • Asset Turnover: 0.61x
  • • Equity Multiplier: 2.19x
  • Recent ROE (-2.10%) is below the historical average (8.59%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2003 21.09% 6.90% 1.19x 2.58x ₩3.79 Billion
2004 6.37% 4.78% 0.57x 2.36x ₩-3.86 Billion
2005 20.46% 7.82% 1.25x 2.08x ₩14.90 Billion
2006 19.04% 8.59% 1.12x 1.99x ₩16.52 Billion
2010 19.44% 13.23% 1.07x 1.38x ₩50.84 Billion
2011 8.96% 7.21% 0.89x 1.39x ₩-6.45 Billion
2012 7.98% 6.61% 0.85x 1.42x ₩-13.54 Billion
2013 8.51% 7.89% 0.80x 1.34x ₩-12.24 Billion
2014 9.40% 8.61% 0.73x 1.49x ₩-5.32 Billion
2015 9.93% 9.06% 0.74x 1.48x ₩-713.55 Million
2016 6.34% 5.26% 0.77x 1.56x ₩-36.34 Billion
2017 5.12% 4.13% 0.76x 1.64x ₩-50.77 Billion
2018 3.25% 2.58% 0.77x 1.63x ₩-71.53 Billion
2019 -0.35% -0.27% 0.70x 1.87x ₩-108.51 Billion
2020 7.25% 5.39% 0.70x 1.92x ₩-30.80 Billion
2021 9.67% 8.01% 0.62x 1.93x ₩-4.27 Billion
2022 4.93% 3.82% 0.68x 1.90x ₩-67.36 Billion
2023 -2.05% -1.64% 0.62x 2.03x ₩-156.66 Billion
2024 -2.10% -1.56% 0.61x 2.19x ₩-151.54 Billion

Industry Comparison

This section compares Green Cross Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $185,563,423,740
  • Average return on equity (ROE) among peers: 1.60%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Green Cross Corp (006280) ₩1.49 Trillion 21.09% 1.14x $552.24 Million
Dongwha Pharm.Co.Ltd (000020) $229.73 Billion 2.15% 0.36x $75.32 Million
Yuhan Corp. (000100) $323.58 Billion 10.19% 0.72x $4.21 Billion
Yuyu Pharma Inc (000227) $128.69 Billion -1.72% 0.50x $26.44 Million
Ildong Holdings Co Ltd (000230) $66.98 Billion 10.88% 1.80x $49.55 Million
Samil Pharm (000520) $62.87 Billion 0.00% 0.77x $110.58 Million
Donga Socio Holdings (000640) $328.69 Billion 10.58% 1.17x $206.35 Million
Jw Pharmac (001060) $223.83 Billion 0.28% 1.65x $278.34 Million
JW Pharmaceutical Corp (001067) $265.44 Billion 13.94% 1.43x $489.75 Million
Samsung Pharm (001360) $77.58 Billion -31.98% 0.20x $65.82 Million
Ahn-Gook Pharmaceutical Co. Ltd (001540) $148.25 Billion 1.71% 0.47x $27.39 Million